MCID: PPL018
MIFTS: 46

Papillary Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Adenocarcinoma

MalaCards integrated aliases for Papillary Adenocarcinoma:

Name: Papillary Adenocarcinoma 12 15 72
Infiltrating and Papillary Adenocarcinoma 12
Infiltrating Papillary Adenocarcinoma 12
Adenocarcinoma, Papillary 44
Adenocarcinoma Papillary 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3112
MeSH 44 D000231
NCIt 50 C2853 C7438
SNOMED-CT 68 4797003 64524002
UMLS 72 C0001420 C1321863

Summaries for Papillary Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures and exhibit compressive, destructive growth that replaces the normal tissue.

MalaCards based summary : Papillary Adenocarcinoma, also known as infiltrating and papillary adenocarcinoma, is related to aggressive digital papillary adenocarcinoma and gastric papillary adenocarcinoma. An important gene associated with Papillary Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Cytoskeletal Signaling and MicroRNAs in cancer. The drugs Letrozole and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and cervix, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Wikipedia : 75 Papillary adenocarcinoma is a histological form of lung cancer that is diagnosed when the malignant... more...

Related Diseases for Papillary Adenocarcinoma

Diseases related to Papillary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 456)
# Related Disease Score Top Affiliating Genes
1 aggressive digital papillary adenocarcinoma 34.6 MUC1 CEACAM5
2 gastric papillary adenocarcinoma 34.3 TP53 ERBB2
3 eccrine papillary adenocarcinoma 34.1 PGR KRT7
4 papillary serous adenocarcinoma 31.4 TP53 PGR NKX2-1 KRT7 BRCA1
5 papillary adenoma 30.8 VIM NKX2-1 KRT7
6 rete testis adenocarcinoma 30.5 NKX2-1 CEACAM5
7 adenocarcinoma 30.5 TP53 MUC1 ERBB2 CDH1
8 fallopian tube adenocarcinoma 30.4 ERBB2 BRCA2 BRCA1
9 cystadenoma 30.4 PGR MUC1 KRT7
10 hidradenoma 30.3 VIM MUC1 KRT7
11 oncocytoma 30.2 VIM MUC1 KRT7
12 adenofibroma 30.2 VIM MUC16 MUC1
13 pulmonary sclerosing hemangioma 30.2 NKX2-1 KRT7
14 mucinous adenocarcinoma 30.2 NKX2-1 MUC1 KRT7
15 endosalpingiosis 30.0 PGR MUC1 KRT7
16 cervical adenocarcinoma 29.9 TP53 PGR KRT7 ERBB2
17 spiradenoma 29.8 TP53 MUC1 KRT7
18 alveoli adenoma 29.8 NKX2-1 KRT7
19 endocervical adenocarcinoma 29.8 VIM TP53 KRT7
20 pseudo-meigs syndrome 29.8 MUC16 CDH1
21 bronchiolo-alveolar adenocarcinoma 29.6 NKX2-1 KRT7 CDH1
22 endometrial adenocarcinoma 29.5 TP53 PGR KRT7 ERBB2
23 sclerosing hemangioma 29.5 PGR NKX2-1 MUC1 KRT7
24 renal cell carcinoma, papillary, 1 29.5 TP53 KRT7 ERBB2
25 barrett esophagus 29.4 TP53 KRT7 ERBB2
26 mucoepidermoid carcinoma 29.3 MUC1 KRT7 ERBB2 CEACAM5
27 adenosquamous carcinoma 29.3 TP53 NKX2-1 MUC1 KRT7
28 cholecystitis 29.3 TP53 MUC1 CDH1
29 serous cystadenocarcinoma 29.3 TP53 PGR MUC16 ERBB2
30 tubular adenocarcinoma 29.3 PGR MUC1 ERBB2 CDH1
31 sweat gland cancer 29.2 TP53 PGR KRT7 ERBB2
32 squamous cell carcinoma 29.1 TP53 MUC1 ERBB2 CDH1
33 renal cell carcinoma, nonpapillary 29.0 VIM NKX2-1 MUC1 KRT7 CDH1
34 mesothelioma, malignant 28.9 VIM NKX2-1 MUC16 MUC1 KRT7 CEACAM5
35 ovarian serous cystadenocarcinoma 28.7 TP53 PGR MUC16 ERBB2
36 transitional cell carcinoma 28.6 TP53 KRT7 ERBB2 CDH1
37 papillary carcinoma 28.6 PGR NKX2-1 MUC1 KRT7 ERBB2 CDH1
38 fallopian tube carcinoma 28.5 TP53 PGR ERBB2 BRCA2 BRCA1
39 in situ carcinoma 28.3 TP53 PGR ERBB2 CDH1 BRCA1
40 gallbladder cancer 28.3 TP53 MUC1 ERBB2 CEACAM5 CDH1
41 carcinosarcoma 28.1 VIM TP53 PGR MUC1 KRT7 ERBB2
42 primary peritoneal carcinoma 27.9 TP53 PGR MUC16 ERBB2 BRCA2 BRCA1
43 cystadenocarcinoma 27.4 TP53 PGR MUC16 MUC1 KRT7 ERBB2
44 pancreatic cancer 27.4 TP53 MUC1 ERBB2 CEACAM5 CDH1 BRCA2
45 gastric adenocarcinoma 27.3 TP53 MUC1 KRT7 ERBB2 CEACAM5 CDH1
46 lung cancer susceptibility 3 27.0 TP53 NKX2-1 MUC1 KRT7 ERBB2 CEACAM5
47 endometrial cancer 26.9 TP53 PGR MUC16 KRT7 ERBB2 CDH1
48 ovarian cancer 26.3 TP53 PGR MUC16 MUC1 KRT7 ERBB2
49 lung papillary adenocarcinoma 12.7
50 fallopian tube papillary adenocarcinoma 12.5

Graphical network of the top 20 diseases related to Papillary Adenocarcinoma:



Diseases related to Papillary Adenocarcinoma

Symptoms & Phenotypes for Papillary Adenocarcinoma

GenomeRNAi Phenotypes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.23 BRCA1 BRCA2 CDH1 ERBB2 KRT7 NKX2-1

MGI Mouse Phenotypes related to Papillary Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.09 BRCA1 BRCA2 CDH1 ERBB2 KRT7 NKX2-1
2 homeostasis/metabolism MP:0005376 9.96 BRCA1 BRCA2 CDH1 ERBB2 KRT7 MST1R
3 endocrine/exocrine gland MP:0005379 9.92 BRCA1 BRCA2 CDH1 ERBB2 MST1R NKX2-1
4 embryo MP:0005380 9.91 BRCA1 BRCA2 CDH1 ERBB2 PGR TP53
5 digestive/alimentary MP:0005381 9.88 BRCA1 BRCA2 CDH1 ERBB2 NKX2-1 TP53
6 neoplasm MP:0002006 9.7 BRCA1 BRCA2 CDH1 ERBB2 NKX2-1 PGR
7 normal MP:0002873 9.5 BRCA1 BRCA2 CDH1 ERBB2 NKX2-1 PGR
8 reproductive system MP:0005389 9.28 BRCA1 BRCA2 CDH1 ERBB2 MST1R NKX2-1

Drugs & Therapeutics for Papillary Adenocarcinoma

Drugs for Papillary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
2
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
3
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
4
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
5
Bevacizumab Approved, Investigational Phase 2 216974-75-3
6
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
7
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
8
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
9
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
10
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
11
Ipilimumab Approved Phase 2 477202-00-9
12
Durvalumab Approved, Investigational Phase 2 1428935-60-7
13
Lenvatinib Approved, Investigational Phase 2 417716-92-8
14
Pembrolizumab Approved Phase 2 1374853-91-4
15
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
16
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
17
Gemcitabine Approved Phase 2 95058-81-4 60750
18
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625
19
Iodine Approved, Investigational Phase 2 7553-56-2 807
20
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
21
Trametinib Approved Phase 2 871700-17-3 11707110
22
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
23
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
24
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
25
nivolumab Approved Phase 2 946414-94-4
26
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
27
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
28
Tremelimumab Investigational Phase 2 745013-59-6
29
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
30
MK-1775 Investigational Phase 2 501-36-0, 955365-80-7 24856436 445154
31
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
32
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
33
Atrasentan Investigational Phase 2 173937-91-2, 195733-43-8 159594
34 Estrogens Phase 2
35 Steroid Synthesis Inhibitors Phase 2
36 Estrogen Receptor Antagonists Phase 2
37 Estrogen Antagonists Phase 2
38 Aromatase Inhibitors Phase 2
39 Hormones Phase 2
40 Antifungal Agents Phase 2
41 Immunoglobulin G Phase 2
42 Mitogens Phase 2
43 Liver Extracts Phase 2
44 Endothelial Growth Factors Phase 2
45 Histone Deacetylase Inhibitors Phase 2
46 Radiopharmaceuticals Phase 2
47 Fluorodeoxyglucose F18 Phase 2
48 Fluorides Phase 2
49 Deoxyglucose Phase 2
50 Antibodies Phase 2

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
2 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
3 Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma Completed NCT00134043 Phase 2 vorinostat
4 A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma Completed NCT00098813 Phase 2 romidepsin
5 A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma Completed NCT00118248 Phase 2 tanespimycin
6 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
7 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
8 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
9 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
10 Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine Completed NCT00085293 Phase 2 Decitabine
11 A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy Completed NCT00729157 Phase 2
12 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
13 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
14 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
15 A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
16 Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy Recruiting NCT03914300 Phase 2 Cabozantinib;Cabozantinib S-malate
17 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Recruiting NCT02973997 Phase 2 Lenvatinib
18 Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers Recruiting NCT02393690 Phase 2 Selumetinib
19 Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer Recruiting NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
20 A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers Recruiting NCT02152995 Phase 2 Trametinib
21 A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
22 Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT01116648 Phase 1, Phase 2 Cediranib Maleate;Olaparib
23 A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
24 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
25 Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
26 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Suspended NCT02978625 Phase 2
27 A Phase II Study of Atrasentan (ABT-627) Plus DOXIL in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Serous Papillary Adenocarcinoma Following Platinum + Taxane Therapy Terminated NCT00653328 Phase 2 atrasentan hydrochloride;doxil
28 A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
29 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
30 A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake Completed NCT01413113 Phase 1 pazopanib hydrochloride
31 Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone Completed NCT01441154
32 Studies on Thyroid Nodules and Thyroid Cancer Recruiting NCT00001160
33 A Pilot Study to Correlate DNA Sequence Copy Number Abnormalities With Outcome in Patients With Advanced Epithelial Ovarian Cancer Withdrawn NCT00053235

Search NIH Clinical Center for Papillary Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, papillary

Genetic Tests for Papillary Adenocarcinoma

Anatomical Context for Papillary Adenocarcinoma

MalaCards organs/tissues related to Papillary Adenocarcinoma:

41
Thyroid, Lung, Cervix, Lymph Node, Pancreas, Liver, Ovary

Publications for Papillary Adenocarcinoma

Articles related to Papillary Adenocarcinoma:

(show top 50) (show all 1351)
# Title Authors PMID Year
1
Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? 9 38
18339419 2008
2
Adult thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with thyroid transcription factor-1 expression. 9 38
17967658 2007
3
Case report of renal pelvic adenocarcinoma associated with a renal stone that produced carbohydrate antigen 125 and carbohydrate antigen 19-9. 9 38
17933139 2007
4
Thyroid transcription factor-1 expression in thyroid-like nasopharyngeal papillary adenocarcinoma: report of 2 cases. 9 38
16084450 2005
5
Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. 9 38
11895489 2002
6
Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. 9 38
11505409 2001
7
[Expression of CD44V6 and nm23-H1 in thyroid papillary adenocarcinoma and lymph node metastasis]. 9 38
10681781 1998
8
Ovarian vein vs peripheral blood CA125 serum levels: a comparative study. 9 38
9234924 1997
9
Cystic brain lesions: cytologic examination and carcinoembryonic antigen assay in fine needle aspirates. 9 38
8629400 1996
10
[A case of intraductal papillary adenocarcinoma in adenoma of the pancreas presenting a mutation of Ki-ras codon 12 in the duodenal juice collected during a secretin test]. 9 38
7474493 1995
11
Factors influencing growth rate of recurrent stomach cancers as determined by analysis of serum carcinoembryonic antigen. 9 38
7889481 1995
12
Small cell carcinoma of the stomach: an immunohistochemical and electron microscopic study. 9 38
1333852 1992
13
Establishment of a human chorionic gonadotropin-producing human gastric carcinoma in nude mice. 9 38
1921405 1991
14
Cardiac tamponade as an initial presentation of papillary carcinoma with psammoma bodies and intranuclear grooves-A diagnostic dilemma. 38
31120622 2019
15
[The effective mutation of epidermal growth factor receptor in synchronous multiple primary lung cancers: study of clinical, radiographic and pathological factors]. 38
31434406 2019
16
Multiple primary lung adenocarcinomas pre-operatively diagnosed by discordant epidermal growth factor receptor mutations. 38
31139414 2019
17
Tumor Budding and Other Risk Factors of Lymph Node Metastasis in Submucosal Early Gastric Carcinoma: A Multicenter Clinicopathologic Study in 621 Radical Gastrectomies of Chinese Patients. 38
31094925 2019
18
Cytological differences between invasive and noninvasive or minimally invasive lung adenocarcinomas diagnosed in Japanese patients using needle biopsy specimens of pulmonary lesions ≤3 cm in diameter. 38
30968597 2019
19
Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma. 38
31287861 2019
20
Nonthyroidal metastatic lesion in thyroid: A missed diagnosis and a lesson learnt. 38
31169237 2019
21
Efficacy and safety of endoscopic submucosal dissection for papillary adenocarcinoma-type early gastric cancer. 38
31232966 2019
22
Thyroid-like low-grade papillary adenocarcinoma of nasopharynx. 38
31177192 2019
23
[Nasopharyngeal low grade papillary adenocarcinoma with squamous differentiation:a case report]. 38
31163537 2019
24
Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study. 38
31395362 2019
25
Primary Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma. 38
31146581 2019
26
Low-grade papillary adenocarcinoma of nasopharynx. Case report and review of the literature. 38
30075860 2019
27
Spontaneous pulmonary adenocarcinoma and subcutaneous cavernous hemangiomas arising in a squirrel monkey (Saimiri sciureus). 38
31148179 2019
28
Genetic analysis of digital papillary adenocarcinoma. 38
31025737 2019
29
Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma. 38
30472730 2019
30
A Case of Endoscopic Mucosal Resection of Carcinoma in Adenoma at the Minor Duodenal Papilla. 38
31182951 2019
31
Polypoid gallbladder tumors with a deep hypoechoic area and a conically thickened outermost hyperechoic layer suggest shallow T2 carcinoma. 38
31205753 2019
32
A case of lung adenocarcinoma complicated by pulmonary talcosis occurring in a patient employed in the confectionery industry. 38
30775827 2019
33
The Risk of Misdiagnosing Pulmonary Adenocarcinoma as Traumatic Pseudocyst in a Young Adult. 38
30315800 2019
34
An autopsy case of anaplastic lymphoma kinase-positive lung cancer exacerbated in a short period of time: a case report. 38
31030664 2019
35
[Digital papillary adenocarcinoma : Four case reports with brief literature review]. 38
30478600 2019
36
Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: low curative resection rate but favorable long-term outcomes after curative resection. 38
30039320 2019
37
[Case of papillary cholangiocarcinoma with curative resection after long-term follow-up]. 38
30626859 2019
38
Recurrent intestinal obstruction in a patient of Peutz-Jeghers syndrome. 38
30880787 2019
39
Thymic papillary adenocarcinoma coexisting with type A thymoma: A case report. 38
30959362 2019
40
Serous Papillary Adenocarcinoma of Unknown Primary in a Recurrent Paravaginal Cyst. 38
31281694 2019
41
Aggressive Digital Papillary Adenocarcinoma at Atypical Site. 38
30792586 2019
42
Carcinosarcoma of Vater's papilla: case report of a rare neoplasm and review of the literature. 38
30706323 2019
43
Endoscopic submucosal dissection of papillary adenocarcinoma of stomach; protocol for a systematic review and meta-analysis. 38
30593208 2018
44
[Resected Cases of Thyroid Tumor Diagnosed Class Ⅲ by Fine Needle Aspiration Cytology]. 38
30692302 2018
45
Foamy Histiocyte-like Esophageal Adenocarcinoma: Unusual Morphology and Diagnostic Pitfalls. 38
30275231 2018
46
Clinicopathological and genetic characteristics associated with brain metastases from lung adenocarcinoma and utility as prognostic factors. 38
30214559 2018
47
Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. 38
29500656 2018
48
Adrenal metastasis in sequentially developed combined hepatocellular carcinoma-cholangiocarcinoma: A case report. 38
30215052 2018
49
[Clinicopathologic features of nasopharyngeal papillary adenocarcinoma]. 38
30122002 2018
50
Aggressive Digital Papillary Adenocarcinoma: Population-Based Analysis of Incidence, Demographics, Treatment, and Outcomes. 38
29578881 2018

Variations for Papillary Adenocarcinoma

Expression for Papillary Adenocarcinoma

Search GEO for disease gene expression data for Papillary Adenocarcinoma.

Pathways for Papillary Adenocarcinoma

GO Terms for Papillary Adenocarcinoma

Cellular components related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA2 BRCA1

Biological processes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.72 TP53 NKX2-1 CDH1 BRCA2 BRCA1
2 positive regulation of gene expression GO:0010628 9.35 VIM TP53 NKX2-1 ERBB2 BRCA1
3 cellular response to indole-3-methanol GO:0071681 9.26 CDH1 BRCA1
4 chordate embryonic development GO:0043009 9.16 BRCA2 BRCA1
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.92 TP53 MUC1 BRCA2 BRCA1

Molecular functions related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 VIM TP53 PGR NKX2-1 MUC16 MUC1
2 enzyme binding GO:0019899 9.35 TP53 PGR NKX2-1 MST1R BRCA1
3 identical protein binding GO:0042802 9.23 VIM TP53 PGR ERBB2 CEACAM5 CDH1

Sources for Papillary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....